Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with knee osteoarthritis (OA).ReNu is a cryopreserved, amniotic suspension allograft (ASA) developed for managing symptomatic knee osteoarthritis.ReNu consists of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and extracellular mat ...